Literature DB >> 3567258

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.

W F Gattaz, M Köllisch, T Thuren, J A Virtanen, P K Kinnunen.   

Abstract

Phospholipase-A2 (PLA2) is a key enzyme in the metabolism of phospholipids, and it may play an important role in neuronal function and neuronal plasticity. We determined the activity of PLA2 in the plasma of 20 drug-free schizophrenic patients, 6 nonschizophrenic psychiatric patients, and 21 healthy controls. Schizophrenic patients showed significantly higher plasma PLA2 activity than controls, and higher than our nonschizophrenic patients. Seventy percent of the schizophrenics had enzyme activity higher than the highest value from the control group. The increased plasma PLA2 activity in schizophrenics was reduced to the level of the controls after 3 weeks of neuroleptic treatment. These findings warrant further study for possible implications of this increased PLA2 activity in the etiopathology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3567258     DOI: 10.1016/0006-3223(87)90164-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  27 in total

1.  Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders.

Authors:  E A Thomas; B Dean; G Pavey; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study.

Authors:  Prachi Semwal; Suman Prasad; Panchami G Varma; A M Bhagwat; S N Deshpande; B K Thelma
Journal:  J Genet       Date:  2002-08       Impact factor: 1.166

Review 3.  Platelet biomarkers in Alzheimer's disease.

Authors:  Leda L Talib; Helena Pg Joaquim; Orestes V Forlenza
Journal:  World J Psychiatry       Date:  2012-12-22

4.  Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family-based samples.

Authors:  K V Chowdari; B Brandstaetter; P Semwal; T Bhatia; S Deshpande; R Reddy; J Wood; C R Weinberg; B K Thelma; V L Nimgaonkar
Journal:  Psychiatr Genet       Date:  2001-12       Impact factor: 2.458

5.  Intracerebral injection of phospholipase A2 inhibits dopamine-mediated behavior in rats: possible implications for schizophrenia.

Authors:  J Brunner; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

6.  Decreased phospholipase A2 activity in cerebrospinal fluid of patients with dementia.

Authors:  Stefan Smesny; Susan Stein; Ingo Willhardt; Jürgen Lasch; Heinrich Sauer
Journal:  J Neural Transm (Vienna)       Date:  2008-06-27       Impact factor: 3.575

7.  Chronic lithium treatment decreases brain phospholipase A2 activity.

Authors:  M C Chang; C R Jones
Journal:  Neurochem Res       Date:  1998-06       Impact factor: 3.996

8.  Role of calcium-independent phospholipase A2 in cortex striatum thalamus cortex circuitry-enzyme inhibition causes vacuous chewing movements in rats.

Authors:  Li-Yen Lee; Wei-Yi Ong; Akhlaq A Farooqui; Jean-Marc Burgunder
Journal:  Psychopharmacology (Berl)       Date:  2007-09-04       Impact factor: 4.530

9.  Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Authors:  S Smesny; B Milleit; U-C Hipler; C Milleit; M R Schäfer; C M Klier; M Holub; I Holzer; G E Berger; M Otto; I Nenadic; M Berk; P D McGorry; H Sauer; G P Amminger
Journal:  Mol Psychiatry       Date:  2013-03-12       Impact factor: 15.992

10.  Effect of fish oils containing different amounts of EPA, DHA, and antioxidants on plasma and brain fatty acids and brain nitric oxide synthase activity in rats.

Authors:  Karin Engström; Ann-Sofie Saldeen; Baichun Yang; Jawahar L Mehta; Tom Saldeen
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.